A Randomized, Prospective, Comparative, Multicenter Study of Rabeprazole and Ranitidine in the Treatment of Reflux Esophagitis.
- Author:
Hyun Yong JEONG
1
;
Byong Seok LEE
;
Jae Kyu SUNG
;
Tae Yong LEE
;
Sae Jin YOON
;
Sun Joo KIM
;
Il Kun CHUNG
;
Suck Ho LEE
;
Jeong Eun SHIN
;
Dong Soo LEE
;
Jong Tae BAEK
;
Soon Woo NAM
;
Sang Jeong YOON
;
Seok Hyun KIM
;
Gye Sung LEE
;
Jong Min LEE
;
An Na KIM
;
Jae In OH
Author Information
1. Department of Internal Medicine, Chungnam National University College of Medicine, Chungnam, Korea. jeonghy@cnu.ac.kr
- Publication Type:Original Article ; Comparative Study ; English Abstract ; Multicenter Study ; Randomized Controlled Trial
- Keywords:
Ranitidine;
Rabeprazole;
Reflux esophagitis
- MeSH:
2-Pyridinylmethylsulfinylbenzimidazoles;
Adult;
Anti-Ulcer Agents/*therapeutic use;
Benzimidazoles/*therapeutic use;
Esophagitis, Peptic/*drug therapy;
Female;
Histamine H2 Antagonists/*therapeutic use;
Humans;
Male;
Middle Aged;
Omeprazole/*analogs & derivatives/therapeutic use;
Proton Pumps/*antagonists & inhibitors;
Proton-Translocating ATPases/therapeutic use;
Ranitidine/*therapeutic use
- From:The Korean Journal of Gastroenterology
2006;47(1):15-21
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: This study was done to evaluate the efficacy of rabeprazole (proton-pump-inhibitor) and ranitidine (H2-receptor antagonist) in the symptom relief and treatment of erosive esophagitis diagnosed by endoscopy. METHODS: A total of 110 patients with typical gastroesophageal reflux disease (GERD) symptoms were enrolled in this multicenter study. They were randomized into rabeprazole group (53 patients) and ranitidine group (57 patients) respectively. The patients in rabeprazole group were given 10 mg of rabeprazole and ranitidine group received 300 mg of ranitidine before breakfast and dinner for 8 weeks. After the end of treatment, we evaluated the endoscopic healing rate of reflux esophagitis and symptomatic improvement. RESULTS: After 8 weeks of treatment, rabeprazole group showed significantly higher complete endoscopic cure rate than ranitidine group (86.8% [46/53] vs. 57.9% [33/57], p=0.001) and higher symptomatic improvement of heartburn (91.2% [31/34] vs. 76.2% [32/42], p=0.085), especially in the first 7 days (76.7% vs. 45.3%, p=0.008). Also, rabeprazole group showed significantly higher improvement of regurgitation symptom than ranitidine group (100% [35/35] vs. 83% [39/47], p=0.009). Both group showed no differences in the improvement of chest pain and globus sensation. All the adverse events (rabeprazole group 4 events vs. ranitidine group 3 events) were mild and there was no abnormality in laboratory test. CONCLUSIONS: In patients with GERD, rabeprazole 10 mg b.i.d. is superior to ranitidine 300 mg b.i.d. in healing of reflux esophagitis and resolving typical GERD symptoms. Rabeprazole is an effective and well-tolerated drug for GERD treatment.
